Compare InMode Ltd (INMD) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Summit Therapeutics Inc — how do they compare? InMode Ltd trades at $14.19 (market cap $809.93M), while Summit Therapeutics Inc trades at $17.45 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 16.9× InMode Ltd's market cap, and InMode Ltd is more actively traded (365,490 versus 6,173,057). Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and Summit Therapeutics Inc for 16 Days on average.
| INMD | SMMT | |
|---|---|---|
Market Cap | $809.93M | $13.71B |
Volume | 365,490 | 6,173,057 |
Sector | Health | Health |
52-Week High | $16.62 | $26.38 |
52-Week Low | $12.76 | $12.43 |
Typical Hold Time | 28 Days | 16 Days |
Enterprise Value | $313.27M | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $14.14, up 0.93% on the day, with bearish technical signals from moving averages but attractive valuation metrics including a P/E of 11.63 and EV/EBITDA of 4.48. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1 2026, while maintaining strong profitability with 76.52% gross margins. Recent developments include the launch of Morpheus8 Cool technology and an unsolicited acquisition offer from Steel Partners at $16.75 per share.
The stock presents value opportunity with solid fundamentals but faces near-term headwinds from cyclical industry softness and management capital allocation concerns. Analyst sentiment is divided with 45% buy ratings versus 55% hold, suggesting cautious optimism amid ongoing strategic review of the acquisition proposal.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
